U.S. FDA issues two observations to Zydus' oncology injectable plant in Ahmedabad

U.S. Food and Drug Administration (FDA) has issued two observations to the oncology injectable plant of Zydus in Ahmedabad.
The observations were issued following a GMP follow-up inspection of the facility in SEZ 1, near Matoda from June 9-18. They were not related to data integrity. The company will closely work with the U.S. FDA to address and respond to the observations in an expeditious manner, Zydus said on Wednesday.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

The Hindu

8 hours ago

• The Hindu

Granules unit in Hyderabad, one of the largest globally for paracetamol API, under U.S. FDA scanner

Generic drugmaker Granules India's active pharmaceutical ingredients (API) manufacturing facility in Bonthapally, Hyderabad, has been issued an observation by the U.S. Food and Drug Administration (U.S. FDA). The Bonthapally facility is one of the world's largest single-site paracetamol API manufacturing plants by volume. Along with paracetamol APIs, the company has established Metformin and Guaifenesin API manufacturing plants in the same facility, Granules India said in an intimation to the stock exchanges on Friday. The U.S. FDA had inspected the facility, located in Sangareddy district, from June 16-20 and issued Form 483 with one observation. The company said it will respond to the observation within the stipulated time.

Hans India

10 hours ago

• Hans India

ZeroHarm Eyes Rs 150 Crore Milestone by FY 2025 -'26, Accelerates Global Expansion into GCC

ZeroHarm Sciences, India's pioneering clean-label nutraceutical company, is set to accelerate its global footprint with a focused expansion into the GCC markets, including the UAE and the broader Middle East. Following a remarkable 10× revenue growth over the past two years and operating at a healthy ~20% EBITDA margin, the company closed the last fiscal year with 71 crore in gross revenue with an exit ARR of 90 crores. In the current fiscal, ZeroHarm is aiming for ₹150 crore in gross revenue, driven by strong domestic and global momentum and increasing traction in the United States, which now contributes nearly 30% of its overall revenue. At the heart of ZeroHarm's global success is its patented ZeroHarm BioEnhance platform, a pharma-grade nanotechnology that encapsulates plant-based actives at the nanoscale, dramatically enhancing their bioavailability by up to 5×, ensuring faster onset, precise dosing, and residue-free delivery. This breakthrough, backed by granted patents and deep R&D, makes ZeroHarm the first Indian company to bring pharmaceutical nanotech into nutraceuticals at scale. ZeroHarm's US FDA, CE, and ISO-certified formulations are backed by government-led clinical trials, with documented claims for 15 products, setting it apart in a market rife with unverified health claims. Today, the company offers over 70 targeted, condition-specific products spanning diabetes, arthritis, PCOS, liver and kidney health, immunity, and oncology support, with over million units sold across India to date. Backed by a fully owned, nanotech-enabled manufacturing facility, ZeroHarm can produce up to ₹250 crore worth of finished goods annually, making it one of the few Indian nutraceutical brands with true end-to-end production capabilities. To support its international expansion, ZeroHarm has acquired a dedicated manufacturing and R&D facility in the United States, enhancing local supply chain efficiency, fast-tracking formulation innovation, and enabling closer clinical and regulatory collaborations in key global markets. The U.S. infrastructure also gives ZeroHarm a significant strategic edge in developed markets, where stringent compliance standards often limit entry for Indian nutraceutical brands reliant on contract manufacturing. 'The global nutraceutical market is shifting, consumers are demanding not just clean labels, but clinical credibility. At ZeroHarm, we've combined deep R&D with pharma-grade nanotechnology to raise the bar for efficacy, safety, and transparency in preventive wellness. Our entry into the GCC is a natural extension of the trust we've built in India and the U.S., and a significant step toward making evidence-backed, plant-based therapeutics accessible to global consumers,' said Sachin Darbarwar, Founder & CEO, ZeroHarm Sciences. With distribution agreements and regulatory filings already underway, the company will also launch in the UK aside from the GCC markets by Q3 2025, introducing its clinically tested product lines via pharmacies, e-commerce platforms, and integrative practitioner networks.

Indian Express

14 hours ago

• Indian Express

Scientists say they may have found a way to extend human lifespan

For decades, scientists have been trying to find a way to extend human lifespan, and while studies have shown that select lab animals can live longer by eating less, they haven't conducted these studies on humans. A century-old study on lab rats has shown that mice who eat less often outlive their fed counterparts, but it can be almost impossible for most humans to follow a permanent diet. However, a new study by the School of Biological Sciences, University of East Anglia, claims that a combination of FDA-approved drugs that mimic the effects of dieting might be the answer to a longer life. The two drugs – Rapamycin and Metformin are known to extend the lifespan of mice as much as up to 30 per cent. Rapamycin, which was first found in the 1970s in bacteria living on the Easter Island soil, has been traditionally used as a powerful immunosuppressant to prevent organ-transplant rejection. The drug works by disabling a particular switch which is used to inform cells when a cell has an abundance of nutrients. As for Metformin, it is a synthetic compound that is found in French Lilac or Goat's Rue, which doctors prescribe to control sugar levels in type 2 diabetes. Since both of these drugs are used to sense the nutrient and energy levels in the human body, biologists wanted to see if the combination of these drugs could have the same effect as eating less. To know more about their effects, scientists say they examined thousands of existing studies and came across 167 studies that focused on eight vertebrate species, like fish and monkeys, which offered them a detailed insight into how these drugs affected animals. Out of three strategies that help with longevity, eating less, taking Rapamycin and consuming Metformin, scientists say the most dependable way to increase the lifespan is to eat less, irrespective of the animal's sex. They also noted that the second most effective strategy to increase lifespan was to take Rapamycin, while Metformin had no substantial effect. However, scientists did say that the effect of Rapamycin on animals wasn't consistent, as, in some cases, studies have shown that eating less or taking Rapamycin reduced an animal's lifespan. Another thing to note here is that most of these positive effects were on mice and rats, which have genes similar to humans but are not exactly the same. And since Rapamycin does come with some side effects, like reduced immunity, scientists are now trying to see if lower doses of the drug offer some advantages without the side effects. According to an ongoing Rapamycin trial on humans, it was noted that lower doses of the drug might help increase the lifespan. But, as of now, the trial is still in progress and will take a few years before the results are out.